Application of umbilical cord Wharton jelly originated mesenchymal stem cells in heart failure cellular transplantation therapy

A technology of mesenchymal stem cells and heart failure, applied in the direction of medical raw materials derived from mammals, cardiovascular system diseases, microorganisms, etc., can solve the problems of reduced para-autocrine function and failure to achieve biological effects, so as to improve prognosis and solve The effect of high mortality

Active Publication Date: 2010-04-07
PLA NAVY GENERAL HOSIPTAL
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to apply the mesenchymal stem cells derived from umbilical cord Huatong jelly to patients with chronic heart failure caused by coronary heart disease and dilated cardiomyopathy as a material for cell transplantation to improve Improve the q

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0017] Example 1 Preparation of UW-MSCs transplantation materials - application of fresh UW-MSCs

[0018] The fresh umbilical cord Wharton's jelly mesenchymal stem cells that have just been subcultured for 2-4 passages were digested with 0.05-0.25% trypsin for 1-5 minutes, serum neutralized, washed 3 times with balanced salt solution, and the centrifugal force of the centrifuge was controlled. Resuspend in 100-1000g with 0.9% sodium chloride injection containing 0-100 units heparin / ml.

Example Embodiment

[0019] Example 2 Preparation of UW-MSCs transplantation materials - using cryopreserved UW-MSCs spares

[0020] Take out the cryopreserved passage 2-4 umbilical cord Wharton's jelly mesenchymal stem cells from the cryogenic container, quickly put them into a 35-38 °C incubator and a water bath, and dissolve within 2 minutes. Resuspend the cells in a complete medium solution. After 2-4 days of cell fusion, re-digest and wash the cells, and use the heparin sodium chloride injection with a concentration of "1000 units of heparin: 100 ml of 0.9% sodium chloride solution" to prepare a cell concentration of 1-2 × 10 6 / ml of cell suspension, usually packed in 10ml per vial.

Example Embodiment

[0021] Example 3 Surgical method of transvenous transplantation of UW-MSCs

[0022] Will 2 x 10 7 The UW-MSCs suspension was diluted in 20 ml of heparinized saline (200 units of heparin + 20 ml of normal saline) by intravenous rapid injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of umbilical cord Wharton jelly originated mesenchymal stem cells used as cellular transplantation materials for treating heart failures caused by coronary heart diseases and dilated cardiomyopathies, wherein the heart failures include chronic ischemic heart failures caused by myocardial infarction, final-stage ischemic heart failures, and the heart failures caused by secondary cardiomyopathies after primary dilated cardiomyopathies and myocarditis.

Description

technical field [0001] The invention relates to the use of biological materials in the medical field, in particular to the application of mesenchymal stem cells prepared from human umbilical cord Huatong jelly in the preparation of heart failure cell transplantation materials caused by coronary heart disease and dilated cardiomyopathy. Background technique [0002] About 17 million people die from cardiovascular diseases worldwide every year. Although the mortality rate of acute myocardial infarction has decreased significantly with the improvement of drug treatment, interventional technology and surgical operation, evidence-based medicine has found that even if the patients with acute myocardial infarction who successfully received early revascularization therapy still have more than 30% of patients develop ischemic heart failure and even develop end-stage ischemic heart failure. End-stage ischemic heart failure refers to: ① a history of myocardial infarction; ② severe cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61P9/04C12N5/08A61K35/51
Inventor 高连如张宁坤陈宇杨晔丁青艾朱智明曹毅
Owner PLA NAVY GENERAL HOSIPTAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap